{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:56:08Z","timestamp":1761663368273,"version":"3.41.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,6,13]],"date-time":"2015-06-13T00:00:00Z","timestamp":1434153600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s10585-015-9727-0","type":"journal-article","created":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T10:55:40Z","timestamp":1434106540000},"page":"555-566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis"],"prefix":"10.1007","volume":"32","author":[{"given":"Jacqueline E.","family":"Reilly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey D.","family":"Neighbors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaxiang","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond J.","family":"Hohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,13]]},"reference":[{"issue":"4","key":"9727_CR1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11745-004-1233-3","volume":"39","author":"SA Holstein","year":"2004","unstructured":"Holstein SA, Hohl RJ (2004) Isoprenoids: remarkable diversity of form and function. Lipids 39(4):293\u2013309","journal-title":"Lipids"},{"issue":"24","key":"9727_CR2","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.282.24.2340","volume":"282","author":"JC LaRosa","year":"1999","unstructured":"LaRosa JC, He J, Vupputuri S (1999) Effect of statins on risk of coronary disease - A meta-analysis of randomized controlled trials. Jama J Am Med Assoc 282(24):2340\u20132346","journal-title":"Jama J Am Med Assoc"},{"issue":"6","key":"9727_CR3","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1053\/j.seminoncol.2007.10.006","volume":"34","author":"F Saad","year":"2007","unstructured":"Saad F, Lipton A (2007) Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol 34(6):S17\u2013S23","journal-title":"Semin Oncol"},{"issue":"1","key":"9727_CR4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","volume":"97","author":"JE Brown","year":"2005","unstructured":"Brown JE et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97(1):59\u201369","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"9727_CR5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","volume":"25","author":"RGG Russell","year":"1999","unstructured":"Russell RGG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25(1):97\u2013106","journal-title":"Bone"},{"issue":"1","key":"9727_CR6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1006\/bbrc.1999.1499","volume":"264","author":"E Beek van","year":"1999","unstructured":"van Beek E et al (1999) Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264(1):108\u2013111","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"9727_CR7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1006\/abbi.1999.1502","volume":"373","author":"JD Bergstrom","year":"2000","unstructured":"Bergstrom JD et al (2000) Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 373(1):231\u2013241","journal-title":"Arch Biochem Biophys"},{"issue":"15","key":"9727_CR8","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1096\/fasebj.4.15.2123808","volume":"4","author":"WA Maltese","year":"1990","unstructured":"Maltese WA (1990) Posttranslational modification of proteins by isoprenoids in mammalian-cells. Faseb J 4(15):3319\u20133328","journal-title":"Faseb J"},{"key":"9727_CR9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.bi.61.070192.002035","volume":"61","author":"S Clarke","year":"1992","unstructured":"Clarke S (1992) Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu Rev Biochem 61:355\u2013386","journal-title":"Annu Rev Biochem"},{"issue":"8","key":"9727_CR10","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1359\/jbmr.2000.15.8.1467","volume":"15","author":"FP Coxon","year":"2000","unstructured":"Coxon FP et al (2000) Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15(8):1467\u20131476","journal-title":"J Bone Miner Res"},{"issue":"1","key":"9727_CR11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00223-002-2017-2","volume":"72","author":"FP Coxon","year":"2003","unstructured":"Coxon FP, Rogers MJ (2003) The role of prenylated small GTP-binding proteins in the regulation of osteoclast function. Calcif Tissue Int 72(1):80\u201384","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"9727_CR12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","volume":"13","author":"SP Luckman","year":"1998","unstructured":"Luckman SP et al (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13(4):581\u2013589","journal-title":"J Bone Miner Res"},{"issue":"9","key":"9727_CR13","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/ncb0901-831","volume":"3","author":"LE O\u2019Brien","year":"2001","unstructured":"O\u2019Brien LE et al (2001) Rac1 orientates epithelial apical polarity through effects on basolateral laminin assembly. Nat Cell Biol 3(9):831\u2013838","journal-title":"Nat Cell Biol"},{"issue":"47","key":"9727_CR14","doi-asserted-by":"crossref","first-page":"6434","DOI":"10.1038\/sj.onc.1203026","volume":"18","author":"MP Quinlan","year":"1999","unstructured":"Quinlan MP (1999) Rac regulates the stability of the adherens junction and its components, thus affecting epithelial cell differentiation and transformation. Oncogene 18(47):6434\u20136442","journal-title":"Oncogene"},{"issue":"11","key":"9727_CR15","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1091\/mbc.11.11.3703","volume":"11","author":"VMM Braga","year":"2000","unstructured":"Braga VMM et al (2000) Activation of the small GTPase Rac is sufficient to disrupt cadherin-dependent cell-cell adhesion in normal human keratinocytes. Mol Biol Cell 11(11):3703\u20133721","journal-title":"Mol Biol Cell"},{"issue":"6","key":"9727_CR16","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1083\/jcb.137.6.1421","volume":"137","author":"VMM Braga","year":"1997","unstructured":"Braga VMM et al (1997) The small GTPases rho and rac are required for the establishment of cadherin-dependent cell-cell contacts. J Cell Biol 137(6):1421\u20131431","journal-title":"J Cell Biol"},{"issue":"4","key":"9727_CR17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1083\/jcb.149.4.775","volume":"149","author":"GCM Zondag","year":"2000","unstructured":"Zondag GCM et al (2000) Oncogenic Ras downregulates Rac activity, which leads to increased Rho activity and epithelial-mesenchymal transition. J Cell Biol 149(4):775\u2013781","journal-title":"J Cell Biol"},{"issue":"1","key":"9727_CR18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1083\/jcb.200103048","volume":"154","author":"RA Worthylake","year":"2001","unstructured":"Worthylake RA et al (2001) RhoA is required for monocyte tail retraction during transendothelial migration. J Cell Biol 154(1):147\u2013160","journal-title":"J Cell Biol"},{"issue":"4","key":"9727_CR19","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1349-7006.2001.tb01113.x","volume":"92","author":"Y Matsumoto","year":"2001","unstructured":"Matsumoto Y et al (2001) Small GTP-binding protein, Rho, both increased and decreased cellular motility, activation of matrix metalloproteinase 2 and invasion of human osteosarcoma cells. Jpn J Cancer Res 92(4):429\u2013438","journal-title":"Jpn J Cancer Res"},{"issue":"5","key":"9727_CR20","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.4049\/jimmunol.162.5.2964","volume":"162","author":"P Adamson","year":"1999","unstructured":"Adamson P et al (1999) Lymphocyte migration through brain endothelial cell monolayers involves signaling through endothelial ICAM-1 via a Rho-dependent pathway. J Immunol 162(5):2964\u20132973","journal-title":"J Immunol"},{"issue":"6795","key":"9727_CR21","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/35020106","volume":"406","author":"EA Clark","year":"2000","unstructured":"Clark EA et al (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406(6795):532\u2013535","journal-title":"Nature"},{"issue":"2","key":"9727_CR22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ncpuro1295","volume":"6","author":"EA Platz","year":"2009","unstructured":"Platz EA (2009) Does statin use affect the risk of developing prostate cancer? Nat Clin Pract Urol 6(2):70\u201371","journal-title":"Nat Clin Pract Urol"},{"issue":"14","key":"9727_CR23","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1002\/cncr.25308","volume":"116","author":"RJ Hamilton","year":"2010","unstructured":"Hamilton RJ et al (2010) Statin medication use and the risk of biochemical recurrence after radical prostatectomy results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 116(14):3389\u20133398","journal-title":"Cancer"},{"issue":"19","key":"9727_CR24","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","volume":"367","author":"SF Nielsen","year":"2012","unstructured":"Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367(19):1792\u20131802","journal-title":"N Engl J Med"},{"issue":"11","key":"9727_CR25","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1055-9965.EPI-07-0599","volume":"16","author":"TJ Murtola","year":"2007","unstructured":"Murtola TJ et al (2007) Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomark Prevent 16(11):2226\u20132232","journal-title":"Cancer Epidemiol Biomark Prevent"},{"issue":"7","key":"9727_CR26","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/ncpuro1146","volume":"5","author":"TJ Murtola","year":"2008","unstructured":"Murtola TJ et al (2008) Statins and prostate cancer prevention: where we are now, and future directions. Nat Clin Pract Urol 5(7):376\u2013387","journal-title":"Nat Clin Pract Urol"},{"issue":"1","key":"9727_CR27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/pcan.2013.34","volume":"17","author":"A Lustman","year":"2014","unstructured":"Lustman A et al (2014) Statin use and incident prostate cancer risk: does the statin brand matter? A population-based cohort study. Prostate Cancer Prostatic Dis 17(1):6\u20139","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"9727_CR28","first-page":"5 U77","volume":"32","author":"O Yu","year":"2014","unstructured":"Yu O et al (2014) Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol 32(1):5 U77","journal-title":"J Clin Oncol"},{"issue":"3","key":"9727_CR29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0163-7258(99)00045-5","volume":"84","author":"A Corsini","year":"1999","unstructured":"Corsini A et al (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84(3):413\u2013428","journal-title":"Pharmacol Ther"},{"issue":"9","key":"9727_CR30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1358\/mf.2002.24.9.802312","volume":"24","author":"RF Reinoso","year":"2002","unstructured":"Reinoso RF et al (2002) Preclinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 24(9):593\u2013613","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"16","key":"9727_CR31","first-page":"3551","volume":"55","author":"A Sasaki","year":"1995","unstructured":"Sasaki A et al (1995) Bisphosphonate risedronate reduces metastatic human breast-cancer burden in bone in nude-mice. Cancer Res 55(16):3551\u20133557","journal-title":"Cancer Res"},{"issue":"4","key":"9727_CR32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.leukres.2010.08.008","volume":"35","author":"SA Holstein","year":"2011","unstructured":"Holstein SA, Hohl RJ (2011) Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells. Leukemia Res 35(4):551\u2013559","journal-title":"Leukemia Res"},{"issue":"3","key":"9727_CR33","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.leukres.2009.06.035","volume":"34","author":"SA Holstein","year":"2010","unstructured":"Holstein SA, Tong HX, Hohl RJ (2010) Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. Leukemia Res 34(3):344\u2013351","journal-title":"Leukemia Res"},{"issue":"2","key":"9727_CR34","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/jpet.110.175521","volume":"337","author":"BM Wasko","year":"2011","unstructured":"Wasko BM, Dudakovic A, Hohl RJ (2011) Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate. J Pharmacol Exp Ther 337(2):540\u2013546","journal-title":"J Pharmacol Exp Ther"},{"key":"9727_CR35","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1096\/fasebj.24.1_supplement.681.15","volume":"24","author":"BM Wasko","year":"2010","unstructured":"Wasko BM et al (2010) Identification and characterization of novel bisphosphonate inhibitors of squalene synthase. Faseb J 24:681","journal-title":"Faseb J"},{"issue":"6","key":"9727_CR36","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/jcb.23087","volume":"112","author":"MM Weivoda","year":"2011","unstructured":"Weivoda MM, Hohl RJ (2011) The effects of direct inhibition of geranylgeranyl pyrophosphate synthase on osteoblast differentiation. J Cell Biochem 112(6):1506\u20131513","journal-title":"J Cell Biochem"},{"issue":"5","key":"9727_CR37","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2174\/187152009788451860","volume":"9","author":"AJ Wiemer","year":"2009","unstructured":"Wiemer AJ, Hohl RJ, Wiemer DF (2009) The intermediate enzymes of isoprenoid metabolism as anticancer targets. Anti-Cancer Agents Med Chem 9(5):526\u2013542","journal-title":"Anti-Cancer Agents Med Chem"},{"key":"9727_CR38","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3762\/bjoc.10.171","volume":"10","author":"X Zhou","year":"2014","unstructured":"Zhou X et al (2014) Synthesis of isoprenoid bisphosphonate ethers through C\u2013P bond formations: potential inhibitors of geranylgeranyl diphosphate synthase. Beilstein J Org Chem 10:1645\u20131650","journal-title":"Beilstein J Org Chem"},{"issue":"5","key":"9727_CR39","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood.V77.5.1064.1064","volume":"77","author":"RJ Hohl","year":"1991","unstructured":"Hohl RJ et al (1991) Inhibition of hydroxymethylglutaryl coenzyme A reductase activity induces a paradoxical increase in DNA synthesis in myeloid leukemia cells. Blood 77(5):1064\u20131070","journal-title":"Blood"},{"issue":"29","key":"9727_CR40","doi-asserted-by":"crossref","first-page":"17508","DOI":"10.1074\/jbc.270.29.17508","volume":"270","author":"RJ Hohl","year":"1995","unstructured":"Hohl RJ, Lewis K (1995) Differential-effects of monoterpenes and lovastatin on ras processing. J Biol Chem 270(29):17508\u201317512","journal-title":"J Biol Chem"},{"issue":"1","key":"9727_CR41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11745-998-0178-x","volume":"33","author":"RJ Hohl","year":"1998","unstructured":"Hohl RJ et al (1998) Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphonic acids. Lipids 33(1):39\u201346","journal-title":"Lipids"},{"issue":"10","key":"9727_CR42","first-page":"3039","volume":"86","author":"RJ Hohl","year":"1995","unstructured":"Hohl RJ, LewisTibesar K (1995) Targeting the isoprenoid pathway for antileukemia therapy in humans. Blood 86(10):3039","journal-title":"Blood"},{"issue":"7","key":"9727_CR43","first-page":"A342","volume":"44","author":"RJ Hohl","year":"1996","unstructured":"Hohl RJ et al (1996) Differential effects of isoprenoid phosphonic acids on RAS farnesylation and cholesterol synthesis. J Investig Med 44(7):A342","journal-title":"J Investig Med"},{"issue":"2","key":"9727_CR44","first-page":"PII39","volume":"59","author":"RJ Hohl","year":"1996","unstructured":"Hohl RJ et al (1996) Inhibition of RAS farnesylation by isoprenoid phosphonic acids. Clin Pharmacol Ther 59(2):PII39","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"9727_CR45","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bone.2011.09.056","volume":"50","author":"MM Weivoda","year":"2012","unstructured":"Weivoda MM, Hohl RJ (2012) Geranylgeranyl pyrophosphate stimulates PPAR gamma expression and adipogenesis through the inhibition of osteoblast differentiation. Bone 50(2):467\u2013476","journal-title":"Bone"},{"key":"9727_CR46","unstructured":"Maalouf MA (2006) Synthesis of isoprenoids incorporating a fluorescent label and evaluation of their effect on the mevalonate pathway. Chemistry. University of Iowa, Iowa City, IA"},{"issue":"8","key":"9727_CR47","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s10585-006-9011-4","volume":"22","author":"JM Drake","year":"2005","unstructured":"Drake JM, Gabriel CL, Henry MD (2005) Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging. Clin Exp Metastasis 22(8):674\u2013684","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"9727_CR48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","volume":"296","author":"JE Dunford","year":"2001","unstructured":"Dunford JE et al (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro nd inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296(2):235\u2013242","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"9727_CR49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ab.2004.09.024","volume":"336","author":"H Tong","year":"2005","unstructured":"Tong H, Holstein SA, Hohl RJ (2005) Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells. Anal Biochem 336(1):51\u201359","journal-title":"Anal Biochem"},{"issue":"1","key":"9727_CR50","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0003-2697(85)90442-7","volume":"150","author":"PK Smith","year":"1985","unstructured":"Smith PK et al (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150(1):76\u201385","journal-title":"Anal Biochem"},{"issue":"8","key":"9727_CR51","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4161\/cbt.9.8.11112","volume":"9","author":"JM Drake","year":"2010","unstructured":"Drake JM, Danke JR, Henry MD (2010) Bone-specific growth inhibition of prostate cancer metastasis by atrasentan. Cancer Biol Ther 9(8):607\u2013614","journal-title":"Cancer Biol Ther"},{"issue":"28","key":"9727_CR52","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1038\/sj.onc.1202792","volume":"18","author":"PM Ghosh","year":"1999","unstructured":"Ghosh PM et al (1999) Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Oncogene 18(28):4120\u20134130","journal-title":"Oncogene"},{"issue":"9","key":"9727_CR53","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1158\/1078-0432.CCR-05-2766","volume":"12","author":"S Wakchoure","year":"2006","unstructured":"Wakchoure S et al (2006) Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res 12(9):2862\u20132868","journal-title":"Clin Cancer Res"},{"issue":"1","key":"9727_CR54","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bone.2010.07.016","volume":"48","author":"P Clezardin","year":"2011","unstructured":"Clezardin P (2011) Bisphosphonates\u2019 antitumor activity: an unravelled side of a multifaceted drug class. Bone 48(1):71\u201379","journal-title":"Bone"},{"issue":"22","key":"9727_CR55","first-page":"6538","volume":"62","author":"P Fournier","year":"2002","unstructured":"Fournier P et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62(22):6538\u20136544","journal-title":"Cancer Res"},{"issue":"5","key":"9727_CR56","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1172\/JCI200422087","volume":"114","author":"E Giraudo","year":"2004","unstructured":"Giraudo E, Inoue M, Hanahan D (2004) An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Investig 114(5):623\u2013633","journal-title":"J Clin Investig"},{"issue":"13","key":"9727_CR57","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","volume":"10","author":"T Hiraga","year":"2004","unstructured":"Hiraga T et al (2004) Zoledronic acid inhibits visceral metastases in the 4T1\/luc mouse breast cancer model. Clin Cancer Res 10(13):4559\u20134567","journal-title":"Clin Cancer Res"},{"issue":"11","key":"9727_CR58","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1002\/cncr.21530","volume":"104","author":"B Ory","year":"2005","unstructured":"Ory B et al (2005) Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 104(11):2522\u20132529","journal-title":"Cancer"},{"key":"9727_CR59","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1471-2407-8-81","volume":"8","author":"JM Tuomela","year":"2008","unstructured":"Tuomela JM et al (2008) Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice. BMC Cancer 8:81","journal-title":"BMC Cancer"},{"issue":"6","key":"9727_CR60","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/S0002-9440(10)63239-7","volume":"165","author":"S Yamagishi","year":"2004","unstructured":"Yamagishi S et al (2004) Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol 165(6):1865\u20131874","journal-title":"Am J Pathol"},{"issue":"9","key":"9727_CR61","first-page":"2708","volume":"62","author":"SS Virtanen","year":"2002","unstructured":"Virtanen SS et al (2002) Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 62(9):2708\u20132714","journal-title":"Cancer Res"},{"issue":"5","key":"9727_CR62","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf L et al (2000) Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol 31(5):578\u2013583","journal-title":"Hum Pathol"},{"issue":"2","key":"9727_CR63","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/pros.22742","volume":"74","author":"G Gandaglia","year":"2014","unstructured":"Gandaglia G et al (2014) Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate 74(2):210\u2013216","journal-title":"Prostate"},{"issue":"24","key":"9727_CR64","doi-asserted-by":"crossref","first-page":"9209","DOI":"10.1158\/0008-5472.CAN-04-2442","volume":"64","author":"RB Shah","year":"2004","unstructured":"Shah RB et al (2004) Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64(24):9209\u20139216","journal-title":"Cancer Res"},{"issue":"5","key":"9727_CR65","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","volume":"38","author":"GH Nancollas","year":"2006","unstructured":"Nancollas GH et al (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38(5):617\u2013627","journal-title":"Bone"},{"issue":"3","key":"9727_CR66","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1210\/me.2007-0158","volume":"22","author":"LS Lyons","year":"2008","unstructured":"Lyons LS et al (2008) Ligand-independent activation of androgen receptors by rho gtpase signaling in prostate cancer. Mol Endocrinol 22(3):597\u2013608","journal-title":"Mol Endocrinol"},{"issue":"32","key":"9727_CR67","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1038\/sj.onc.1207708","volume":"23","author":"S Knight-Krajewski","year":"2004","unstructured":"Knight-Krajewski S et al (2004) Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells. Oncogene 23(32):5513\u20135522","journal-title":"Oncogene"},{"issue":"12","key":"9727_CR68","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1158\/0008-5472.CAN-11-2502","volume":"72","author":"K-T Lin","year":"2012","unstructured":"Lin K-T et al (2012) Vav3-Rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence. Cancer Res 72(12):3000\u20133009","journal-title":"Cancer Res"},{"issue":"16","key":"9727_CR69","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/onc.2009.30","volume":"28","author":"J Qin","year":"2009","unstructured":"Qin J et al (2009) Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis. Oncogene 28(16):1853\u20131863","journal-title":"Oncogene"},{"issue":"2","key":"9727_CR70","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1677\/ERC-06-0036","volume":"14","author":"R Engers","year":"2007","unstructured":"Engers R et al (2007) Prognostic relevance of increased Rac GTPase expression in prostate carcinomas. Endocr Relat Cancer 14(2):245\u2013256","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"9727_CR71","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00054556","volume":"6","author":"DW Russell","year":"1992","unstructured":"Russell DW (1992) Cholesterol-biosynthesis and metabolism. Cardiovasc Drugs Ther 6(2):103\u2013110","journal-title":"Cardiovasc Drugs Ther"},{"key":"9727_CR72","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1146\/annurev.bi.51.070182.003011","volume":"51","author":"GJ Schroepfer","year":"1982","unstructured":"Schroepfer GJ (1982) Sterol biosynthesis. Annu Rev Biochem 51:555\u2013585","journal-title":"Annu Rev Biochem"},{"issue":"51","key":"9727_CR73","doi-asserted-by":"crossref","first-page":"41793","DOI":"10.1074\/jbc.M504101200","volume":"280","author":"S Murthy","year":"2005","unstructured":"Murthy S, Tong H, Hohl RJ (2005) Regulation of fatty acid synthesis by farnesyl pyrophosphate. J Biol Chem 280(51):41793\u201341804","journal-title":"J Biol Chem"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-015-9727-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10585-015-9727-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-015-9727-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T15:38:41Z","timestamp":1748446721000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10585-015-9727-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,13]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["9727"],"URL":"https:\/\/doi.org\/10.1007\/s10585-015-9727-0","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"type":"print","value":"0262-0898"},{"type":"electronic","value":"1573-7276"}],"subject":[],"published":{"date-parts":[[2015,6,13]]}}}